Ubs Asset Management Americas Inc Xenon Pharmaceuticals Inc. Transaction History
Ubs Asset Management Americas Inc
- $477 Billion
- Q2 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 404,384 shares of XENE stock, worth $16 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
404,384
Previous 63,568
536.14%
Holding current value
$16 Million
Previous $2.13 Million
493.67%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding XENE
# of Institutions
221Shares Held
73.2MCall Options Held
336KPut Options Held
309K-
Avoro Capital Advisors LLC New York, NY5.4MShares$214 Million3.08% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.34MShares$171 Million1.31% of portfolio
-
Braidwell LP Stamford, CT3.61MShares$143 Million6.91% of portfolio
-
Janus Henderson Group PLC London, X03.58MShares$141 Million0.06% of portfolio
-
Capital International Investors Los Angeles, CA3.18MShares$126 Million0.02% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.46B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...